Cerliponase alfa

Therapeutic indications

Cerliponase alfa is indicated for:

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, tripeptidyl peptidase 1 (TPP1) deficiency

Population group: only adults (18 - 65 years old)

Cerliponase alfa is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, tripeptidyl peptidase 1 (TPP1) deficiency

Population group: only minors (0 - 18 years old)

Cerliponase alfa is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cerliponase alfa is contraindicated in the following cases:

Ventriculo-peritoneal shunts

Ventriculoperitoneal shunt

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: BRINEURA Solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈